Transgene’s CTA for TG6050 Receives French National Agency’s Approval to Initiate P-I Trial for Non-Small Cell Lung Cancer
Shots:
- The French National Agency for the ANSM approved Transgene’s CTA for the company to proceed into P-I clinical trial (Delivir) to evaluate TG6050 for which the 1st patient is expected to be enrolled by H1’23
- The P-I clinical trial (Delivir) will evaluate TG6050 (IV, single & repeated escalating doses) in patients (n=36) with metastatic/advanced NSCLC who have failed standard therapeutic options incl. ICIs across multiple locations
- TG6050 is an oncolytic virus developed using the company’s Invir.IO platform & has been engineered to encode human IL-12 stimulating a powerful antitumor immune response and a full-length anti-CTLA4 Ab
Ref: BusinessWire | Image: Transgene
Related News:- AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
